Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis
用于治疗特发性肺纤维化的人抗 WISP1 抗体
基本信息
- 批准号:8785946
- 负责人:
- 金额:$ 22.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-18 至 2016-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAerosolsAffectAlveolarAmericanAntibodiesAttenuatedBackBleomycinCellsCicatrixClinicalCollaborationsComorbidityCoughingDataDepositionDevelopmentDiseaseDrug Delivery SystemsDrug KineticsEpithelialEpithelial CellsEtiologyEvaluationEventExerciseExtracellular MatrixFDA approvedFatal OutcomeFibroblastsFibrosisFutureGrowth FactorHamman-Rich syndromeHumanHyperplasiaImmunotherapyIn VitroIntravenousKineticsLeft lungLibrariesLifeLife ExpectancyLungLung TransplantationMatrix MetalloproteinasesMediatingMesenchymalModelingMonoclonal AntibodiesOutcomePathway interactionsPharmaceutical PreparationsPharmacologic SubstancePhaseProcessProductionPulmonary FibrosisPulmonologyRegulationRespiratory FailureRiskRouteSafetyShortness of BreathSignal TransductionSignaling ProteinSolidStimulusStructure of parenchyma of lungSurfaceSymptomsSyndromeTherapeuticTissuesUniversitiesWISP1 geneWNT1 geneanalytical methodautocrinebasebiophysical propertiescandidate identificationcell injurydesigndrug developmentextracellularhuman WISP1 proteinin vivomethod developmentmigrationneutralizing antibodynovelparacrinepre-clinicalpublic health relevanceresearch study
项目摘要
DESCRIPTION (provided by applicant): New anti-fibrotic drugs are needed to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, chronically debilitating clinical syndrome with unknown etiology and a terminal outcome. IPF symptoms include persistent cough, progressive severe shortness of breath and decreased exercise capacity. Up to 200,000 Americans suffer from this disease with expected survival limited to 3-5 years. There are currently no approved US drugs leaving lung transplantation as the only option to extend life. IPF is initially characterized by alveolar epithelial cell injury followed by epithelial-mesenchymal transition (EMT) and exaggerated fibroblast migration, activation and proliferation with extracellular matrix deposition and tissue remodeling. When a sufficient proportion of the IPF lung becomes scarred respiratory failure and comorbidities occur. WNT1- Inducible Signaling Protein-1 (WISP1; also known as CCN4) is an autocrine and paracrine extracellular stimulus for EMT. Studies have shown that: 1. WISP1 is induced in human lung cells by TGF-¿; 2. WISP1 is upregulated at the alveolar epithelial surface in IPF; 3. WISP1 protein stimulates EMT and fibroblast ECM deposition in vitro; 4. depletion of WISP1 with neutralizing antibodies attenuates bleomycin-induced pulmonary fibrosis in vivo. Currently, no IPF drugs are in development that target WISP1 or the WNT pathway. Together with our collaborators we have outlined experiments that will harness a powerful combination of antibody discovery, fibrotic pathway expertise and aerosol drug development to provide a solid basis for the discovery, evaluation and development of an anti-WISP1 immunotherapy for IPF treatment.
描述(由申请人提供):需要新的抗纤维化药物治疗特发性肺纤维化(IPF)。IPF是一种进行性,慢性衰弱的临床综合征,病因不明,终末结果。IPF症状包括持续咳嗽,进行性严重呼吸短促和运动能力下降。多达20万美国人患有这种疾病,预计生存期为3-5年。目前还没有批准的美国药物将肺移植作为延长生命的唯一选择。IPF的最初特征是肺泡上皮细胞损伤,随后是上皮-间质转化(EMT),成纤维细胞迁移、活化和增殖过度,伴有细胞外基质沉积和组织重塑。当足够比例的IPF肺变成疤痕时,就会出现呼吸衰竭和合并症。WNT1-诱导信号蛋白-1 (WISP1,也称为CCN4)是EMT的自分泌和旁分泌细胞外刺激。研究表明:1。TGF-¿在人肺细胞中诱导WISP1;2. IPF中肺泡上皮表面WISP1表达上调;3. WISP1蛋白在体外刺激EMT和成纤维细胞ECM沉积;4. 在体内用中和抗体去除WISP1可减轻博莱霉素诱导的肺纤维化。目前,还没有针对WISP1或WNT通路的IPF药物正在开发中。与我们的合作者一起,我们概述了实验,将利用抗体发现,纤维化途径专业知识和气溶胶药物开发的强大组合,为发现,评估和开发用于IPF治疗的抗wisp1免疫疗法提供坚实的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gunnar Joerg Floris Kaufmann其他文献
Gunnar Joerg Floris Kaufmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gunnar Joerg Floris Kaufmann', 18)}}的其他基金
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
一流的 ETS 抑制剂 TK216:转化生物学和口服剂型开发
- 批准号:
10259473 - 财政年份:2021
- 资助金额:
$ 22.48万 - 项目类别:
Selective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA)
选择性雄激素受体降解剂(SARD)作为脊髓和延髓肌萎缩症(SBMA)的新疗法
- 批准号:
10259452 - 财政年份:2021
- 资助金额:
$ 22.48万 - 项目类别:
Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery
抗假单胞菌免疫治疗和靶向药物递送
- 批准号:
8785992 - 财政年份:2014
- 资助金额:
$ 22.48万 - 项目类别:
Human monoclonal antibodies for prevention of S. aureus infections
用于预防金黄色葡萄球菌感染的人单克隆抗体
- 批准号:
8851014 - 财政年份:2012
- 资助金额:
$ 22.48万 - 项目类别:
Human monoclonal antibodies for prevention of S. aureus infections
用于预防金黄色葡萄球菌感染的人单克隆抗体
- 批准号:
8882238 - 财政年份:2012
- 资助金额:
$ 22.48万 - 项目类别:
Bacterial acyl homoserine lactones as immune modulators and drug targets
作为免疫调节剂和药物靶点的细菌酰基高丝氨酸内酯
- 批准号:
8069912 - 财政年份:2010
- 资助金额:
$ 22.48万 - 项目类别:
Bacterial acyl homoserine lactones as immune modulators and drug targets
作为免疫调节剂和药物靶点的细菌酰基高丝氨酸内酯
- 批准号:
7772996 - 财政年份:2010
- 资助金额:
$ 22.48万 - 项目类别:
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy
细菌群体感应作为抗感染免疫治疗的目标
- 批准号:
8015378 - 财政年份:2009
- 资助金额:
$ 22.48万 - 项目类别:
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy
细菌群体感应作为抗感染免疫治疗的目标
- 批准号:
7769569 - 财政年份:2009
- 资助金额:
$ 22.48万 - 项目类别:
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy
细菌群体感应作为抗感染免疫治疗的目标
- 批准号:
7663497 - 财政年份:2009
- 资助金额:
$ 22.48万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 22.48万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 22.48万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 22.48万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 22.48万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 22.48万 - 项目类别:
Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 22.48万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 22.48万 - 项目类别:
Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 22.48万 - 项目类别:
Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 22.48万 - 项目类别:
Small Business Research Initiative














{{item.name}}会员




